Sung Lee Biography and Net Worth

EVP, Chief Financial Officer of Cytokinetics

Sung joined us as Executive Vice President and Chief Financial Officer in May 2024.

Sung is an experienced CFO who brings more than 20 years of finance leadership expertise in the biopharmaceutical and technology businesses to Cytokinetics. Prior to Cytokinetics, Sung was the CFO at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics. He also spent 14 years at Gilead Sciences, where he served in roles of increasing responsibility and scope, including Senior Vice President, Financial Planning & Analysis and Investor Relations. Sung began his career in the tax advisory business at PwC.

He currently serves on the Board of Directors of Tango Therapeutics, a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines.

Sung received a bachelor’s degree in economics from the University of California, Irvine and a Master of Business Taxation degree from the University of Southern California.

Sung is married, a father of two daughters, and has a passion for interior design. He is also a lifelong LA Dodgers fan.

What is Sung Lee's net worth?: The estimated net worth of Sung Lee is at least $5.42 million as of March 17th, 2026. Mr. Lee owns 87,127 shares of Cytokinetics stock worth more than $5,418,428 as of March 19th. This net worth evaluation does not reflect any other assets that Mr. Lee may own. Learn More about Sung Lee's net worth.
How do I contact Sung Lee?: The corporate mailing address for Mr. Lee and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Sung Lee's contact information.
Has Sung Lee been buying or selling shares of Cytokinetics?: During the past quarter, Sung Lee has sold $306,710.25 in Cytokinetics stock. Most recently, Sung Lee sold 4,935 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a transaction totalling $306,710.25. Following the completion of the sale, the executive vice president now directly owns 87,127 shares of the company's stock, valued at $5,414,943.05. Learn More on Sung Lee's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Andrew Callos (EVP), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Sung Lee (EVP, Chief Financial Officer), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), Wendell Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 59 times. They sold a total of 423,190 shares worth more than $23,883,980.51. The most recent insider tranaction occured on March, 18th when EVP Andrew Callos sold 1,930 shares worth more than $119,795.10. Insiders at Cytokinetics own 2.7% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 3/18/2026.

Sung Lee Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/17/2026	Sell	4,935	$62.15	$306,710.25	87,127

Sung Lee Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $61.71

$60.82

$63.03

50 Day Range

MA: $63.80

$60.00

$70.10

2 Week Range

Now: $61.71

$29.31

$70.98

Volume

1,983,803 shs

Average Volume

2,103,726 shs

Market Capitalization

$7.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56